Table 2.
Number and severity of adverse events
SOC (n = 21)Im + SOC (n = 20)
Adverse eventPatients numbers with severity ≥1Average severity scoreImatinib relatedPatients numbers with severity ≥1Average severity scoreImatinib related
Itching/skin reaction/rash 0 (0%) 0 (0; 0–0) NA 0 (0%) 0 (0; 0–0) NA 
Edema 0 (0%) 0 (0; 0–0) NA 0 (0%) 0 (0; 0–0) NA 
Fever 21 (100%) 2.4 (0.74; 1–3) NA 20 (100%) 2.2 (0.67; 1–3) 0 (0; 0–0) 
Headache 4 (19.0%) 0.2 (0.40; 0–1) NA 3 (15.0%) 0.2 (0.37; 0–1) 0 (0; 0–0) 
Body aches/pain 0 (0%) 0 (0; 0–0) NA 0 (0%) 0 (0; 0–0) NA 
Nausea 0 (0%) 0 (0; 0–0) NA 1 (5.0%) 0.05 (0.22; 0–1) 0 (0; 0–0) 
Vomiting 0 (0%) 0 (0; 0–0) NA 0 (0%) 0 (0; 0–0) NA 
Diarrhea 2 (9.5%) 0.10 (0.30; 0–1) NA 2 (10.0%) 0.10 (0.31; 0–1) 0 (0; 0–0) 
Anemia 2 (9.5%) 0.10 (0.30; 0–1) NA 1 (10.0%) 0.05 (0.22; 0–1) 0 (0; 0–0) 
Jaundice 1 (4.8%) 0.05 (0.22; 0–1) NA 0 (0%) 0 (0; 0–0) NA 
SOC (n = 21)Im + SOC (n = 20)
Adverse eventPatients numbers with severity ≥1Average severity scoreImatinib relatedPatients numbers with severity ≥1Average severity scoreImatinib related
Itching/skin reaction/rash 0 (0%) 0 (0; 0–0) NA 0 (0%) 0 (0; 0–0) NA 
Edema 0 (0%) 0 (0; 0–0) NA 0 (0%) 0 (0; 0–0) NA 
Fever 21 (100%) 2.4 (0.74; 1–3) NA 20 (100%) 2.2 (0.67; 1–3) 0 (0; 0–0) 
Headache 4 (19.0%) 0.2 (0.40; 0–1) NA 3 (15.0%) 0.2 (0.37; 0–1) 0 (0; 0–0) 
Body aches/pain 0 (0%) 0 (0; 0–0) NA 0 (0%) 0 (0; 0–0) NA 
Nausea 0 (0%) 0 (0; 0–0) NA 1 (5.0%) 0.05 (0.22; 0–1) 0 (0; 0–0) 
Vomiting 0 (0%) 0 (0; 0–0) NA 0 (0%) 0 (0; 0–0) NA 
Diarrhea 2 (9.5%) 0.10 (0.30; 0–1) NA 2 (10.0%) 0.10 (0.31; 0–1) 0 (0; 0–0) 
Anemia 2 (9.5%) 0.10 (0.30; 0–1) NA 1 (10.0%) 0.05 (0.22; 0–1) 0 (0; 0–0) 
Jaundice 1 (4.8%) 0.05 (0.22; 0–1) NA 0 (0%) 0 (0; 0–0) NA 

Data are presented as n (%) or mean (SD; range). Severity score of 0, 1, 2, and 3 represent normal, mild, moderate, and severe, respectively (see Table S3 for additional information). NA, not applicable.

or Create an Account

Close Modal
Close Modal